Last updated on March 2019

A Study of ABBV-927 and ABBV-181 an Immunotherapy in Subjects With Advanced Solid Tumors

Brief description of study

This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.

Clinical Study Identifier: NCT02988960

Find a site near you

Start Over

Virginia Cancer Specialists /ID# 155266

Fairfax, VA United States
  Connect »